Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior ...

Prime Minister Mark Carney said Wednesday during a pre-budget speech that Canada’s goal over the next decade is to “double ...

Economic and demographic trends in the United States mirror those of other pre-revolutionary societies in the past.

New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the studyAnti-tumour activity observed across all dose levels and in various tumour indicationsNEWCASTLE, ...

Sarytogan Graphite has secured US$2.2 million from prominent Kazakh investor Dias Sarenov to fast-track the definitive ...

Middle-class shoppers flock to brands like The North Face and Dillard's as signs of their material comfort, and they aren't shy about it.

Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...

My Study Life is a really efficient scheduler. T he main utility of the My Study Life app is its scheduling capabilities. You ...

Many Indian students see Ivy League universities as a gateway to global recognition. Early preparation and a holistic ...

The artificial intelligence (AI)-based risk tool GRACE 3.0 may better identify patients with non-ST-elevation acute coronary ...

Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating PotentialUNIONDALE, NY, ...